Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFR(V)-EDV-Dox |
Synonyms | |
Therapy Description |
EGFR(V)-EDV-Dox is a formulation of EGFR bispecific antibodies coupled with nanocellular compounds containing therapeutic dose of doxorubicin, which delivers the cytotoxic doxorubicin to tumor cells over expressing EGFR, leading to anti-tumor activities (PMID: 26279503). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFR(V)-EDV-Dox | EGFR Antibody 60 | EGFR(V)-EDV-Dox is a formulation of EGFR bispecific antibodies coupled with nanocellular compounds containing therapeutic dose of doxorubicin, which delivers the cytotoxic doxorubicin to tumor cells over expressing EGFR, leading to anti-tumor activities (PMID: 26279503). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02766699 | Phase I | EGFR(V)-EDV-Dox | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV) | Unknown status | USA | 0 |